Overview of drug therapy for multiple myeloma
Explore this paper's citation graph
Summary
Bortezomib is approved in the US and Europe as single-agent therapy for the treatment of relapsed or refractory multiple myeloma and thalidomide, its analogues, and arsenic trioxide have demonstrated activity and are under investigation in this disease.
- Type
- review
- Published
- 2005-09-01
- Cited by
- 17
- References
- 102
- OpenAlex
- https://openalex.org/W2044968820
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:6615323
Keywords
Medicine, Lenalidomide, Multiple myeloma, Thalidomide, Bortezomib
References
- Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.
- Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.
- Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
- Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis.
- Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients.
- Single‐Dose Oral Pharmacokinetics of Three Formulations of Thalidomide in Healthy Male Volunteers
- A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
- Proteasome inhibition measurements: clinical application.
- The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
- Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.
- The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis.
- Effective treatment of advanced multiple myeloma refractory to alkylating agents.
- Platelet-collagen interaction: is GPVI the central receptor?
- Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells.
- Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
- A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.
- Molecular sequelae of proteasome inhibition in human multiple myeloma cells
- Single versus double autologous stem-cell transplantation for multiple myeloma.
- An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment.
Cited by
- Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP.
- Traitement du myélome du sujet âgé : intérêt des nouvelles molécules
- Ciprofloxacin-induced G2 arrest and apoptosis in TK6 lymphoblastoid cells is not dependent on DNA double-strand break formation
- Isoliquiritigenin inhibits the growth of multiple myeloma via blocking IL-6 signaling
- Chemotherapy and Survival for Patients With Multiple Myeloma: Findings From a Large Nationwide and Population-Based Cohort
- Autologous peripheral stem cell transplant for POEMS syndrome: A case report
- Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
- Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study.
- Combining the ras inhibitor salirasib and proteasome inhibitors: A potential treatment for multiple Myeloma
- Magnetic Nanoheterostructures: Diagnostic, Imaging and Treatment
- Role of activated nuclear factor‐κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck
- Chapter 11 - Other Nonbiological Approaches to Targeted Cancer Chemotherapy
- Multiple Myeloma: Role of Magnetic Nanoparticles
- NF-κB, IκB Kinase and Interacting Signal Networks in Squamous Cell Carcinomas
- Other Approaches to Targeted Therapy
- BASIC SCIENCE REVIEW
- EPIDEMIOLOGIA DEL MIELOMA MULTIPLO E CARATTERISTICHE CLINICHE DEI PAZIENTI Epidemiology of multiple myeloma and clinical characterization of patients
- Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPAR cross talk with NF- B and C/EBP
Related papers
- Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies
- Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
- Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database
- Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
- Lenalidomide: the emerging role of a novel targeted agent in malignancies.
- Mechanism of action of lenalidomide in hematological malignancies
- [Action mechanism of lenalidomide in hematological malignancies - review].
- New Immunomodulatory Drugs in Myeloma
- Sequential Therapy with IMID's in Relapsed-Refractory Multiple Myeloma Patients.
- Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.